Press release summary
HERLEV, Denmark โ Nordic Bioscience said Nov. 16 that Roche Diagnostics has made an Endotrophin research prototype assay available on cobas e801 analyzers at Nordic Bioscienceโs CLIA laboratory.
The sandwich immunoassay measures intact Endotrophin, a 77-amino-acid signaling peptide released during formation of type VI collagen. Researchers are studying the biomarkerโs relationship to fibrosis, inflammation and adverse outcomes in cardiovascular, kidney and metabolic disease. Nordic Bioscience said Endotrophin has been measured in more than 50,000 patients across cardio-kidney-metabolic studies.
The prototype is the second biomarker from the companiesโ collaboration to reach a Roche platform, following the CE-marked Elecsys PRO-C3 test. The release cited studies associating elevated Endotrophin with mortality and adverse outcomes in heart failure with preserved ejection fraction, as well as kidney-function decline. The assay remains a research prototype and is not presented as an authorized diagnostic test.
Why it matters: Moving a biomarker assay onto a high-throughput clinical laboratory analyzer can make it easier to incorporate into multicenter studies and drug-development programs. Laboratories should distinguish this availability milestone from clinical validation or regulatory clearance and evaluate analytical performance, specimen requirements and study-specific controls before use.
Read the original Nov. 16 release from Nordic Bioscience via PR Newswire.







Leave a Reply